
Oncol Res Treat 2022;45(suppl 1):7–284Abstracts 23
Indication of source:
1. Freedman, R.A., et al. 2019. 37(13): p. 1081-1089.
2. Modi, S., et al. 2021. 81(4 Supplement): p. PD3-06-PD3-06.
3. Jerusalem, G., et al. Annals of Oncology, 2020. 31: p. S63-S64.
Disclosure Statement: e authors declare that there are conicts of interest. e
connections were submitted to the congress organizer KUKM GmbH and KUKM
can disclose them if needed.
246
Implementation of new tests and treatments for patients
with advanced triple negative breast cancer in routine
care – data from the registry platform OPAL
Mark-Oliver Zahn1; Anja Welt2; Marc Thill3; Elmar Stickeler4;
Matthias Zaiss5; Arnd Nusch6; Erik Engel7; Marco Chiabudini8;
Lisa Kruggel8; Martina Jänicke8; Norbert Marschner5; Achim Wöckel9;
Nadia Harbeck10; Thomas Decker11
1Überörtliche Berufsausübungsgemeinschaft MVZ Onkologische Kooperation
Harz, Goslar, Deutschland
2Universitätsklinikum Essen Innere Klinik Tumorforschung, Essen, Deutschland
3Agaplesion Markus Krankenhaus Klinik für Gynäkologie und Gynäkologische
Onkologie, Frankfurt a.M., Deutschland
4Uniklinik RWTH Aachen, Gynäkologie und Geburtsmedizin, Aachen,
Deutschland
5Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg i.Br., Deutschland
6Praxis für Hämatologie und internistische Onkologie, Ratingen, Deutschland
7Hämatologisch-Onkologische Praxis Altona (HOPA), Hamburg, Deutschland
8iOMEDICO, Freiburg i.Br., Deutschland
9Universitätsklinikum Würzburg Frauenklinik und Poliklinik, Würzburg,
Deutschland
10LMU Klinikum München, Brustzentrum, Frauenklinik, München, Deutschland
11Studienzentrum Onkologie Ravensburg Prof. Dr. Dechow, Prof. Dr. Decker,
Dr.Nonnenbroich GbR, Ravensburg, Deutschland
Background: Since 2019, new treatment options for patients (pts) with
advanced triple negative breast cancer (TNBC) have been approved in the
EU: PARP inhibitors for pts with BRCA-mutated and PD-L1 inhibitors
for pts with PD-L1 positive BC. e OPAL registry platform was used to
analyze the implementation of these new tests and treatments into routine
care.
Methods: OPAL (NCT03417115) is a prospective registry that continues
the Tumor Registry Breast Cancer. By March 2022, a total of 3883 pts
with advanced BC had been recruited, of whom 1883 since start of OPAL
(01/2018). Details on all (sequential) treatments, patient and tumor char-
acteristics, biomarker testing, and outcomes are collected. Here data were
analyzed for 254 OPAL pts with TNBC.
Result: Overall, most frequent rst-line regimens since 2018 were (nab)
paclitaxel ±bevacizumab (BEV) (23%), (nab)paclitaxel +atezolizumab
(21%), capecitabine ±BEV (19%), (nab)paclitaxel +carboplatin ±BEV
(10%) and carboplatin +gemcitabine (4%). Second-line (n=98), most
frequent treatments were anthracyclines (18%) and eribulin (17%). Since
2018, the PD-L1 testing rate at start of rst-line treatment has increased
from 14% to 74%. Out of 133 pts tested, 63 pts (47%) had a positive test
result, 53 since the approval of checkpoint-inhibitor atezolizumab (ATZ)
in 08/2019. 41 out of 53 pts (77%) were treated with ATZ rst-line. e
testing rate for BRCA1 or BRCA2 mutations was between 9-14%. Out of
30 pts tested, 3 pts carried a mutation, but no use of PARP-inhibitors was
documented so far in rst-line. Prior to approval of ATZ, median PFS and
OS was 6.4 months (95% CI 5.4-7.3) and 14.9 months (95% CI 12.3-18.4),
respectively. Aer approval of ATZ, the majority of all TNBC pts were still
alive. Updated data will be presented.
Conclusion: Our data show that PD-L1 testing and the new treatment
option for PD-L1 positive tumors were quickly implemented in routine
care. BRCA1/2 testing is performed less oen, especially in rst-line sit-
uation. With longer follow-up, OPAL will show the impact of these new
targeted therapies on the outcome in routine care.
Disclosure Statement: e authors declare that there are conicts of interest. e
connections were submitted to the congress organizer KUKM GmbH and KUKM
can disclose them if needed.
269
AXSANA – EUBREAST 3 (AXillary Surgery After NeoAdjuvant
Treatment): An international prospective multicenter cohort
study of the EUBREAST study group to evaluate dierent
surgical methods of axillary staging (sentinel lymph node
biopsy, targeted axillary dissection, axillary dissection) in
clinically node-positive breast cancer patients treated with
neoadjuvant chemotherapy (NCT04373655)
Maggie Banys-Paluchowski1,2; Ste Hartmann3; Elmar Stickeler4;
Jana de Boniface5,6; Oreste Gentilini7; Sarah Fröhlich3; Marc Thill8;
Franziska Ruf1; Michael Hauptmann9; Güldeniz Karadeniz Cakmak10;
Isabel Teresa Rubio11; Maria Luisa Gasparri12,13; Michalis Kontos14;
Eduard-Alexandru Bonci15,16; Laura Niinikoski17; Rosa DI Micco7;
Dawid Murawa18; David Pinto19; Florentia Peintinger20,21; Lukas Dostalek22;
Christine Solbach23; Matilda Appelgren5; Jens-Uwe Blohmer24;
Elisabeth Thiemann25; Michael Weigel26; Gabriele Kaltenecker27; Kerstin
Ramaker28; Michael G. Schrauder29; Thorsten Kühn30
1Department of Obstetrics and Gynecology, University Hospital of Schleswig
Holstein, Campus Lübeck, Lübeck, Deutschland
2Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf,
Deutschland
3University Hospital Rostock, Department of Gynecology and Obstetrics,
Rostock, Deutschland
4University Hospital Aachen, Department of Gynecology and Obstetrics, Aachen,
Deutschland
5Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm,
Schweden
6Capio St. Göran’s Hospital, Dept. of Surgery, Stockholm, Schweden
7San Raaele Hospital Milan, Milano, Italien
8AGAPLESION Markus Krankenhaus, Department of Gynecology and
Gynecological Oncology, Frankfurt am Main, Deutschland
9Brandenburg Medical School Theodor Fontane, Neuruppin, Deutschland
10Zonguldak BEUN The School of Medicine, General Surgery Department, Breast
and Endocrine Unit, Kozlu/Zonguldak, Türkei
11Breast Surgical Unit, Clínica Universidad de Navarra, Madrid, Spanien
12Department of Gynecology and Obstetrics, Ente Ospedaliero Cantonale,
Ospedale Regionale di Lugano, Lugano, Schweiz
13University of the Italian Switzerland (USI), Faculty of Biomedicine, Lugano,
Schweiz
141st Department of Surgery, Laiko Hospital, National and Kapodistrian
University of Athens, Athens, Griechenland
15Department of Surgical Oncology, ”Prof. Dr. Ion Chiricuță” Institute of
Oncology, Cluj-Napoca, Rumänien
1611th Department of Oncological Surgery and Gynecological Oncology, “Iuliu
Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Rumänien
17Breast Surgery Unit, Comprehensive Cancer Center, Helsinki University
Hospital, University of Helsinki, Finnland
18Department of General Surgery and Surgical Oncology, Collegium Medicum,
University of Zielona Góra, Zielona Góra, Polen
19Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation,
Lisboa, Portugal
20Institute of Pathology, Medical Univ. Graz, Graz, Österreich
21Department of Gynecology, LKH Leoben, Leoben, Österreich
22Gynecologic Oncology Center, Department of Obstetrics and Gynecology,
First Faculty of Medicine, Charles University, General University Hospital, Prague,
Tschechische Republik
23Breast Center, Department of Gynecology and Obstetrics, University of
Frankfurt, Frankfurt, Deutschland
24Department of Gynecology and Breast Cancer Center, Charité Berlin, Berlin,
Deutschland
25Brustzentrum Osnabrück - Niels-Stensen-Kliniken, Osnabrück, Deutschland
26Leopoldina-Krankenhaus, Schweinfurt, Deutschland
27Städtisches Klinikum Karlsruhe Frauenklinik, Karlsruhe, Deutschland
28Regio Klinikum Pinneberg, Pinneberg, Deutschland
29Klinikum Aschaenburg-Alzenau, Aschaenburg, Deutschland
30Department of Gynecology and Obstetrics, Klinikum Esslingen, Esslingen,
Deutschland
Background: e optimal surgical staging procedure of the axilla in
patients who convert from a clinically positive to a clinically negative node
status through neoadjuvant chemotherapy is still controversial. Widely
diverse techniques such as Axillary Lymph Node Dissection (ALND),
Downloaded from http://karger.com/ort/article-pdf/45/Suppl. 3/6/4143722/000521004.pdf by guest on 05 March 2024